Experience

Myelo Therapeutics GmbH

• Germany
• Biotechnology
• 1 - 100 Employee

• Senior Lead and Regulatory Scientist

  • Aug 2021 - Nov 2022

  Berlin, Germany My role is to oversee and manage the development of Myelo001 into a countermeasure against acute radiation syndrome under the NIH contract and as a treatment to chemotherapy induced myeloid suppression.



Charité - University Medicine Berlin

• Research
• 100 - 200 Employee

• Senior Postdoctoral Scientist

  • Jan 2020 - Jul 2021

  Berlin Area, Germany



Icahn School of Medicine at Mount Sinai

• United States
• Hospitals and Health Care
• 700 & Above Employee

• Postdoctoral Fellow

  • Jul 2018 - Jan 2020

  Greater New York City Area My project is to study the immune response and chronic inflammatory response during atherosclerosis progression using both murine model and human atherosclerotic plaque with a specific focus on NKT cells and CD8 T cells. In order to understand the underlaying mechanism of how NKT cells and CD8 T cells contribute to atherosclerosis, I am setting up a murine model to mirror our findings in human.



Mount Sinai Health System

• United States
• Hospitals and Health Care
• 700 & Above Employee

• Postdoctoral Fellow

  • Jun 2016 - Jun 2018

  Greater New York City Area A postdoctoral research studying vaccine development for Human Rhinoviruses (HRVs). My project is to generate novel monoclonal antibodies against HRVs and characterize the epitope to isolate potential vaccine candidate. I was also involved in studying immune responses, with a special interest in the tissue resident Alveolar Macrophages, elicited by broadly neutralizing and non-neutralizing anti-influenza antibodies.



Yale University Careers

• United States
• Higher Education
• 700 & Above Employee

• Postdoc Associate

  • Mar 2013 - Jun 2016

  New Haven My project was to study the impact of aging on influenza infection in murine model. I have throughly characterized both the innate and adaptive immune response against influenza viral infection in young and aged mice. During the characterization, I have documented that 1). aging reduce numbers of alveolar macrophages by lowering the rate of self-renewal; 2). aging impairs the phagocytic functions of alveolar macrophages with or without influenza infection; 3). alveolar macrophages produce more… Show more My project was to study the impact of aging on influenza infection in murine model. I have throughly characterized both the innate and adaptive immune response against influenza viral infection in young and aged mice. During the characterization, I have documented that 1). aging reduce numbers of alveolar macrophages by lowering the rate of self-renewal; 2). aging impairs the phagocytic functions of alveolar macrophages with or without influenza infection; 3). alveolar macrophages produce more Type I interferon post influenza and RSV infection. In addition to my primary research, I was also involved in serval other aging studying including aging and atherosclerosis and impacts of aging on organ transplantation. Show less